• Title/Summary/Keyword: Li-Fraumeni syndrome

Search Result 3, Processing Time 0.079 seconds

Breast Cancer after Radiation Therapy in a Patient with Li-Fraumeni Syndrome: A Case Report (Li-Fraumeni 증후군 환자에서 방사선 치료 후 발생한 유방암: 증례 보고)

  • In Na Yoon;Eun Suk Cha;Jeoung Hyun Kim;Jee Eun Lee;Jin Chung
    • Journal of the Korean Society of Radiology
    • /
    • v.83 no.1
    • /
    • pp.246-251
    • /
    • 2022
  • Li-Fraumeni syndrome (LFS) is an inherited autosomal-dominant tumor-predisposition disorder caused by germline mutations in the TP53 tumor suppressor gene. Since patients with LFS are likely to develop therapy-related cancers, radiation therapy should be avoided if breast cancer is found in these individuals. Herein, we present a case of secondary breast cancer in an LFS patient after radiation and chemotherapy for the first diagnosed breast sarcoma.

Osteosarcoma with Adenocarcinoma of Lung in Li-Fraumeni Syndrome: A Case Report (골육종과 폐선암을 동반한 리-프라우메니 증후군: 증례 보고)

  • Oh, Chang-Seon;Lee, Jin-Ho;Jung, Sung-Taek;Na, Bo-Ram
    • The Journal of the Korean bone and joint tumor society
    • /
    • v.20 no.2
    • /
    • pp.99-103
    • /
    • 2014
  • Li-Fraumeni syndrome (LFS) is an autosomal dominant hereditary disorder characterised by a variety of different tumor types in children and young adults. That contains with a germline mutation in the tumor suppressor gene Tumor Protein p53 (TP53). That is extremely rare. Furthermore, this is sometimes overlooked. Here, we report a case of LFS which was confirmed by mutational analysis of the p53 gene. Also, literature review is intended to improve understanding of this disease entity.

Pediatric High Grade Gliomas in the Context of Cancer Predisposition Syndromes

  • Michaeli, Orli;Tabori, Uri
    • Journal of Korean Neurosurgical Society
    • /
    • v.61 no.3
    • /
    • pp.319-332
    • /
    • 2018
  • Germline mutations in cancer causing genes result in high risk of developing cancer throughout life. These cancer predisposition syndromes (CPS) are especially prevalent in childhood brain tumors and impact both the patient's and other family members' survival. Knowledge of specific CPS may alter the management of the cancer, offer novel targeted therapies which may improve survival for these patients, and enables early detection of other malignancies. This review focuses on the role of CPS in pediatric high grade gliomas (PHGG), the deadliest group of childhood brain tumors. Genetic aspects and clinical features are depicted, allowing clinicians to identify and diagnose these syndromes. Challenges in the management of PHGG in the context of each CPS and the promise of innovative options of treatment and surveillance guidelines are discussed with the hope of improving outcome for individuals with these devastating syndromes.